RESOURCES FROM KACTUS
Article: KLK2: The New Promising Target for Prostate Cancer
KACTUS has recently published a blog discussing about KLK2, a new rising star in the prostate cancer research field.
Prostate cancer research is entering a new era. While PSMA (Prostate-Specific Membrane Antigen) has long been the “gold standard” for targeting, a new star is rising: Human Kallikrein 2 (KLK2).
Traditionally viewed only as a secreted protein, recent breakthroughs have revealed that KLK2 is also expressed on the cell surface of prostate cancer cells. This discovery, coupled with its highly specific expression profile, makes it an exceptionally promising target for next-generation therapeutics.
Why is KLK2 gaining so much attention?
High Specificity: KLK2 is restricted to prostate tissue, showing even more consistent expression across different disease stages than PSMA.
Clinical Momentum: The KLK2-targeting bispecific T-cell engager, Pasritamig, has recently shown impressive results in Phase 1 trials, leading it to skip Phase 2 and head straight to Phase 3.
Versatile Applications: From CAR-T cell therapies to Radioimmunoconjugates, KLK2’s unique structure and internalization properties make it ideal for various modalities.
At LAB-A-PORTER, we are committed to bringing the most innovative tools to your bench. Through our partnership with KACTUS, we now provide high-quality, recombinant KLK2 proteins—including the active form and biotinylated versions—validated for ELISA and BLI assays to accelerate your drug discovery programs.
*All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.
ABOUT KACTUS
Provides quality recombinant proteins and enzymes that accelerate therapeutic development
Founded in 2018, KACTUS is a leading manufacturer of recombinant proteins and enzymes, providing both off-the-shelf products and custom protein services. Their extensive catalog includes over 3,000 recombinant proteins, featuring antibody drug targets, cytokines, transmembrane proteins, MHC monomers and tetramers, immune checkpoint proteins, biotinylated proteins, and more. They also offer AAV titration ELISA kits, GMP-grade gene editing enzymes, and other GMP enzymes. All their products undergo rigorous testing for purity and bioactivity to ensure quality performance and consistency. KACTUS is ISO 13485:2016 certified and operates state-of-the-art facilities, including a 10,000 sq. meter GMP-grade manufacturing site.